Difference between revisions of "Part:BBa K1942000:Experience"
Line 11: | Line 11: | ||
[[File:NJU_China_2016_iGEM_Parts_Description_K1942000_Figure_2.png]] | [[File:NJU_China_2016_iGEM_Parts_Description_K1942000_Figure_2.png]] | ||
+ | |||
+ | Figure 1. Protein quantitatively analysis of K-ras protein after transfection of KRAS siRNA | ||
==== CHARACTERIZATION ==== | ==== CHARACTERIZATION ==== | ||
To ensure the interference efficiency of anti-KRAS siRNA plasmid, we transfected it into human Lung adenocarcinoma cell line A549 and then extracted protein to perform a western blotting. Significant downregulation of K-ras can be observed in A549 cells treating with anti-KRAS siRNA, demonstrating that anti-KRAS siRNA has a gene silencing effect on Lung cancer cells. | To ensure the interference efficiency of anti-KRAS siRNA plasmid, we transfected it into human Lung adenocarcinoma cell line A549 and then extracted protein to perform a western blotting. Significant downregulation of K-ras can be observed in A549 cells treating with anti-KRAS siRNA, demonstrating that anti-KRAS siRNA has a gene silencing effect on Lung cancer cells. | ||
− | |||
− | |||
− | |||
− | |||
===User Reviews=== | ===User Reviews=== |
Revision as of 08:15, 13 October 2016
This experience page is provided so that any user may enter their experience using this part.
Please enter
how you used this part and how it worked out.
Applications of BBa_K1942000
USAGE AND BIOLOGY
We package KRAS siRNA into exosomes by transfecting HEK293 cells with a plasmid expressing KRAS siRNA and then collect siRNA-encapsulated exosomes. When inject the modified exosomes into the vein, exosome will specifically recognize integrin receptors and fuse with Lung adenocarcinoma cells under the direction of the iRGD peptide. Once inside cells, KRAS siRNA will degrade KRAS mRNA by base-pairing, resulting in sharp decrease of K-ras in Lung cancer cells. As a consequence, K-ras reduction and disturbed function will result in the inhabitation of the proliferation of cancer cells, which ultimately have some therapeutic effects on Lung cancer.
Figure 1. Protein quantitatively analysis of K-ras protein after transfection of KRAS siRNA
CHARACTERIZATION
To ensure the interference efficiency of anti-KRAS siRNA plasmid, we transfected it into human Lung adenocarcinoma cell line A549 and then extracted protein to perform a western blotting. Significant downregulation of K-ras can be observed in A549 cells treating with anti-KRAS siRNA, demonstrating that anti-KRAS siRNA has a gene silencing effect on Lung cancer cells.
User Reviews
UNIQ25041e647c2027a1-partinfo-00000000-QINU UNIQ25041e647c2027a1-partinfo-00000001-QINU